Site Editor

Rebecca Olin, MD, MS

Advertisement
Advertisement

Keith W. Pratz, MD, on Gilteritinib With Induction and Consolidation Chemotherapies in AML

Posted: Tuesday, December 15, 2020

Keith W. Pratz, MD, of the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses results from his phase I study of gilteritinib in combination with induction and consolidation chemotherapies in patients with newly diagnosed acute myeloid leukemia, as well as the clinical implications, should subsequent trials confirm the efficacy and safety of gilteritinib in this setting.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.